What are the recommended first‑line medications for binge‑eating disorder, including dosing, contraindications, and alternative pharmacologic options?

Best Medications for Binge Eating Disorder

Lisdexamfetamine (LDX) is the first-line pharmacological treatment for binge eating disorder, as it is the only FDA-approved medication specifically for this indication and demonstrates robust efficacy in reducing binge episodes and promoting weight loss. 1, 2, 3

Treatment Algorithm

First-Line Approach

Always begin with structured behavioral/lifestyle therapy combined with cognitive behavioral therapy (CBT) or other psychological interventions 4. This is the foundation of treatment (Grade A evidence).

When to Add Pharmacotherapy

Add medication when:

• Minimal or no response to psychotherapy alone by 6 weeks
• Patient preference for combined treatment
• Presence of comorbid conditions (obesity, ADHD, depression)
• Need for more rapid symptom control

Medication Options

Primary Choice: Lisdexamfetamine (LDX)

• Dosing: Start at 30 mg daily, titrate up to 50-70 mg daily based on response
• Efficacy: Robust effect sizes for binge episode reduction, remission rates, and relapse prevention 3, 5
• Additional benefit: Produces weight loss (approximately 4.6 kg) 6
• Contraindications:
  • Uncontrolled hypertension
  • History of cardiovascular disease (use with caution)
  • Glaucoma
  • Agitated states
  • History of drug abuse
  • Within 14 days of MAOI use 1
  • Anxiety disorders (use with caution)
• Common side effects: Dry mouth, insomnia, increased heart rate, constipation, anxiety 1, 6
• Monitoring: Heart rate and blood pressure at each visit

Alternative: Topiramate (Off-Label)

• Dosing: Start 25 mg daily, gradually titrate to 200-400 mg daily (typically given as phentermine/topiramate ER 3.75/23 mg initially, then 7.5/46 mg, up to 15/92 mg)
• Efficacy: Comparable to lisdexamfetamine for reducing binge episodes (MD -1.63 vs placebo) 6
• Additional benefit: Greatest weight loss among options (approximately 5.5 kg) 6
• Use when:
  • LDX contraindicated or not tolerated
  • Comorbid obesity is primary concern
  • Patient has seizure disorder (preferred agent) 4
• Contraindications:
  • Glaucoma (avoid) 4
  • Pregnancy (teratogenic)
  • Maximal dose should be used cautiously with anxiety disorders 4
• Common side effects: Cognitive slowing, paresthesias, metabolic acidosis

Alternative: Bupropion-Containing Medications

• Options: Naltrexone ER/bupropion ER combination or bupropion alone
• Dosing: Naltrexone ER 32 mg/bupropion ER 360 mg daily (titrated over 4 weeks)
• Use when:
  • Comorbid depression or nicotine use disorder
  • Patient cannot tolerate stimulants
• Contraindications:
  • Seizure disorder (avoid) 4
  • Within 14 days of MAOI use 4
  • Uncontrolled hypertension (use with caution, monitor heart rate/BP) 4
  • Glaucoma (use with caution) 4
  • Patients already on antidepressants (use with caution or avoid) 4
• Efficacy: Less robust evidence for binge reduction compared to LDX or topiramate 6

Alternative: SSRIs (Off-Label)

• Options: Fluoxetine 60 mg daily, sertraline, citalopram
• Use when:
  • Comorbid depression or anxiety disorders
  • Night eating syndrome variant 4
• Efficacy: Modest benefit for binge eating; primarily treats comorbid mood/anxiety symptoms

Emerging Option: GLP-1 Receptor Agonists

• Options: Liraglutide 3 mg, semaglutide, tirzepatide
• Use when: Comorbid obesity is significant concern
• Evidence: Preliminary data suggests reduction in binge eating in individuals with obesity 7, 8
• Note: Not yet established as standard treatment for BED specifically

Special Populations

With Comorbid Depression

• Preferred: Orlistat, liraglutide 3 mg, or phentermine/topiramate ER at low doses 4
• Avoid or use cautiously: Lorcaserin, naltrexone ER/bupropion ER (especially if already on antidepressants) 4

With Comorbid ADHD

• Preferred: Lisdexamfetamine (treats both conditions) 7, 9
• Alternative: Atomoxetine 7

With Cardiovascular Disease

• Preferred: Orlistat 4
• Use with caution and careful monitoring: Liraglutide 3 mg, phentermine/topiramate ER, naltrexone ER/bupropion ER 4

Critical Pitfalls to Avoid

1. Do not use medications as monotherapy - Always combine with structured behavioral therapy and CBT 4

2. Screen for binge eating disorder before prescribing weight-loss medications - BED is often unrecognized 4

3. Monitor for mood disorders, depression, and suicidal ideation in all patients undergoing treatment 4

4. Avoid weight gain-inducing medications when treating comorbid conditions (e.g., avoid olanzapine, clozapine, mirtazapine, valproate) 7

5. Check for drug interactions - particularly with MAOIs, serotonergic drugs, and other psychotropics 4

Duration and Monitoring

• Continue medication if weight-loss and binge-eating goals are met
• Monitor cardiovascular parameters (heart rate, blood pressure) regularly with stimulants and sympathomimetics
• Assess treatment response by 6 weeks; consider alternative if inadequate response
• Long-term data on sustained efficacy is limited for most agents except psychological interventions